Yishan Li
Co-Founder & Executive ChairmanDr. Yishan Li, also known as Peter, Ph.D., M.B.A, is Executive Chairman of BlossomHill Therapeutics, Inc. from June 2020 and is its Co-Founder. He was a co-founder of Turning Point Therapeutics, Inc. and served as its Director from October 2013 to April 22, 2019. Dr. Li served as Executive Officer of Turning Point Therapeutics, Inc. from April 22, 2019 to May 31, 2019. Dr. Li served as Head of Turning Point Therapeutics, Asia at Turning Point Therapeutics, Inc. since September 2018. Dr. Li served as Chairman of Turning Point Therapeutics from October 2015 until September 2018, Chief Executive Officer from October 2013 until September 2018 and President from October 2013 until April 2018. Dr. Li serves as the President at Turning Point Therapeutics, Inc and served as its Chief Executive Officer. Dr. Li served as a Vice President at Kenson Ventures, LLC. He served as Executive Vice President at Epitomics, Inc. At his current position, Dr. Li consulted for biotech startups on business strategies, operations, marketing and business development in his capacities as a member of Board of Directors, an observer to the Board, or a business advisor. He worked in biotechnology corporate finance at investment bank RBC Capital Markets while Dr. Li was in business school. Prior to business school, he was at Santa Cruz Biotechnology, Inc. in charge of product development, production and quality assurance for a major portion of the company's product line. Prior to that, Dr. Li was a Postdoctoral Research fellow at the Department of Molecular and Cell Biology, University of California. His scientific work focused on protein expression, small molecule-protein interaction, protein structure-function relationship and mechanisms of enzymes. He serves as Chairman of the Board of Turning Point Therapeutics, Inc. Dr. Li has business and scientific experience. He received his Ph.D. in biochemistry from Ohio State University, where Dr. Li was a University Presidential Fellow. He earned his M.B.A. from University of California, Berkeley and his B.S. from University of Science and Technology of China.
Positions
- Company NameBlossomHill Therapeutics, Inc.Stock CodeBLSMPositionCo-Founder & Executive ChairmanColleagues
- JJJingrong Jean CuiScientific Founder, President, CEO & Director
- JAJason A. KeyesCFO & Executive VP
- GOGeoff OxnardChief Medical Officer & Executive VP
- VLVincent LiptakGeneral Counsel & Executive VP
- BCBihua ChenIndependent Director
- SKSheila K. GujrathiLead Independent Director
- JPJohn P. SchmidIndependent Director
